Skip to content
value.today

iSpecimen Inc.

Total raised
$32 M
3 rounds on record
Latest round
$21 M
Dec 2021
First round on record
Aug 2012
Today
Went public
See the company page

iSpecimen Inc. is listed today as iSpecimen Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of iSpecimen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$3 MPrivate placement after listing$2 to $10 million

iSpecimen Inc.: Private sale, May 2026

Investors in this round

2 investors had bought by the notice of May 14, 2026: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for iSpecimen Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katharyn Field · Executive Officer · Chief Executive Officer
  • Anthony Lau · Director
  • Arphing (Tommy) Lee · Director
  • Avtar Dhaliwal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • E.F. Hutton & Co. (CRD 000322687) · New York, New YorkSold in FL, and outside the US

Signed by Katharyn Field, Chief Executive Officer. Source: SEC Form D, newest notice filed May 14, 2026. Read the notice at the SEC.

equity, optionsSEC
Dec 2025$6 MPrivate placement after listing$2 to $10 million

iSpecimen Inc.: Private sale, Dec 2025

Investors in this round

3 investors had bought by the notice of Jan 5, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for iSpecimen Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$220,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katharyn Field · Executive Officer · Chief Executive Officer
  • Anthony Lau · Director
  • Arphing (Tommy) Lee · Director
  • Avtar Dhaliwal · Director
  • Siyun Yang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • E.F. Hutton & Co. (CRD 000322687) · New York, New YorkSold in DE, FL, and outside the US

Signed by Katharyn Field, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 5, 2026. Read the notice at the SEC.

equitySEC
Aug 2025$2 MPrivate placement after listingUnder $2 million

iSpecimen Inc.: Private sale, Aug 2025

Investors in this round

4 investors had bought by the notice of Aug 6, 2025: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for iSpecimen Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$70,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katharyn Bradley Field · Executive Officer · President
  • Robert Bradley Lim · Executive Officer
  • Anthony Bradley Lau · Director
  • Avtar Bradley Dhaliwal · Director
  • Siyun Bradley Yang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Westpark Capital, Inc (CRD 000039914) · New York, New YorkSold in DE, FL

Signed by Katharyn Field, President. Source: SEC Form D, newest notice filed Aug 6, 2025. Read the notice at the SEC.

equity, optionsSEC
Dec 2021$21 MNo. 3$10 to $50 million

iSpecimen Inc.: Raise no. 3, Dec 2021

Investors in this round

4 investors had bought by the notice of Dec 9, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for iSpecimen Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,334,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin J. Bielak · Executive Officer
  • Christopher J. Ianelli · Executive Officer, Director
  • Jill J. Mullan · Executive Officer, Director
  • Tracy J. Curley · Executive Officer
  • Andrew J. Ross · Director
  • George J. Scholl · Director
  • John L. Brooks III · Director
  • Margaret H. Lawrence · Director
  • Steven J. Gullans · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ThinkEquity LLC (CRD 20996) · New York, New YorkSold in CT, NY

Signed by Christopher J. Ianelli, President and CEO. Source: SEC Form D, newest notice filed Dec 9, 2021. Read the notice at the SEC.

equity, optionsSEC
Aug 2014$9 MNo. 2$2 to $10 million

iSpecimen Inc.: Raise no. 2, Aug 2014

Investors in this round

13 investors had bought by the notice of Sep 5, 2014: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for iSpecimen Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce Cranna · Executive Officer
  • Christopher Ianelli · Executive Officer, Director
  • Jill Mullan · Executive Officer, Director
  • Andrew Ross · Director
  • George Scholl · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$8,000,000 worth of equity will come from new investments; $561,041 of equity will come from the cancellation of indebtedness.”

Signed by Christopher Ianelli, President. Source: SEC Form D, newest notice filed Sep 5, 2014. Read the notice at the SEC.

equitySEC
Aug 2012$2 MNo. 1$2 to $10 million

iSpecimen Inc.: Raise no. 1, Aug 2012

Investors in this round

10 investors had bought by the notice of Sep 25, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for iSpecimen Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher John Ianelli · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “1 Year salary - CEO”

Signed by Bruce Cranna, Treasurer. Source: SEC Form D, newest notice filed Sep 25, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company iSpecimen Inc., its revenue in fiscal 2025 came from these product and service lines: Shipping and other $190,000 (10%).

    Annual report (SEC XBRL) · Dec 2025

  • iSpecimen Inc. chose not to state its revenue in its newest notice of a funding round (May 2026).

    SEC Form D · May 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · May 2026

Products and services#

No products or services of iSpecimen Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in iSpecimen Inc.
InvestorKindAmountRoundRoleSource
Andrew L. RossPersonnot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Christopher IanelliPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3
Jill MullanPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3
OBF Investments, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 13 investors.

Largest shareholders today

Institutions holding iSpecimen Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by iSpecimen Inc.
NameRoleNamed in
Katharyn FieldChief Executive OfficerMay 2026
Katharyn Bradley FieldPresidentAug 2025
Robert Bradley LimExecutive officerAug 2025
Benjamin J. BielakExecutive officerDec 2021
Christopher J. IanelliExecutive officerDec 2021
Jill J. MullanExecutive officerDec 2021
Tracy J. CurleyExecutive officerDec 2021
Bruce CrannaExecutive officerSep 2014
Christopher IanelliExecutive officerSep 2014
Jill MullanExecutive officerSep 2014
Christopher John IanelliExecutive officerSep 2012
Anthony LauDirectorMay 2026
Arphing (Tommy) LeeDirectorMay 2026
Avtar DhaliwalDirectorMay 2026
Siyun YangDirectorJan 2026
Anthony Bradley LauDirectorAug 2025
Avtar Bradley DhaliwalDirectorAug 2025
Siyun Bradley YangDirectorAug 2025
Andrew J. RossDirectorDec 2021
Christopher J. IanelliDirectorDec 2021
George J. SchollDirectorDec 2021
Jill J. MullanDirectorDec 2021
John L. Brooks IIIDirectorDec 2021
Margaret H. LawrenceDirectorDec 2021
Steven J. GullansDirectorDec 2021
Andrew RossDirectorSep 2014
Christopher IanelliDirectorSep 2014
George SchollDirectorSep 2014
Jill MullanDirectorSep 2014

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.